Core Insights - BioCardia, Inc. will provide a corporate update and report its financial results for Q2 2025 on August 11, 2025, at 4:30 PM ET [1] - The company specializes in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases [4] Company Overview - BioCardia is headquartered in Sunnyvale, California, and is recognized as a global leader in its field [4] - The company has developed two main biotherapeutic platforms: CardiAMP autologous and CardiALLO™ allogeneic cell therapies, with three clinical stage product candidates currently in development [4] - BioCardia's therapies are supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms [4] Conference Call Details - Participants can register for the conference call via a specific link and will receive their dial-in number upon registration [2] - For those not registered, U.S. callers can dial 1-833-316-0559, while international callers should use 1-412-317-5730, with a recommendation to join the call 10 minutes early [2] - A live webcast of the call will also be available through a provided link [2] Replay Information - A replay of the conference call will be accessible approximately one hour after its conclusion through the same links [3] - Telephonic replay options are available for domestic and international callers using specific access codes [3]

Core Viewpoint - BioCardia, Inc. will provide a corporate update and report its financial results for Q1 2025 on May 14, 2025, at 4:30 PM EDT, followed by a Q&A session [1]. Group 1: Corporate Update - The conference call will include management's formal remarks and a question-and-answer session [1]. - Participants can register for the conference through a provided link [2]. Group 2: Call Details - Registered participants will receive their dial-in number upon registration, with specific numbers for U.S. and international callers [3]. - The conference call will also be available via a live webcast [3]. Group 3: Replay Information - A webcast replay will be available approximately one hour after the call until May 28, 2025 [4]. - A telephonic replay can be accessed using specific numbers and an access code [4]. Group 4: Company Overview - BioCardia, Inc. is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with three cardiac clinical stage product candidates [5]. - The company utilizes its Helix™ biotherapeutic delivery and Morph vascular navigation product platforms for its therapies [5].